- Home
- PLD vs SNY Comparison
PLD vs SNY Comparison
Compare PLD & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLD
- SNY
- Stock Information
- Founded
- PLD 1983
- SNY 1994
- Country
- PLD United States
- SNY France
- Employees
- PLD N/A
- SNY N/A
- Industry
- PLD Real Estate Investment Trusts
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- PLD Real Estate
- SNY Health Care
- Exchange
- PLD Nasdaq
- SNY Nasdaq
- Market Cap
- PLD 105.6B
- SNY 113.4B
- IPO Year
- PLD 1994
- SNY N/A
- Fundamental
- Price
- PLD $115.36
- SNY $47.03
- Analyst Decision
- PLD Buy
- SNY Buy
- Analyst Count
- PLD 17
- SNY 4
- Target Price
- PLD $120.87
- SNY $61.50
- AVG Volume (30 Days)
- PLD 3.2M
- SNY 2.8M
- Earning Date
- PLD 10-15-2025
- SNY 10-24-2025
- Dividend Yield
- PLD 3.50%
- SNY 3.40%
- EPS Growth
- PLD 21.80
- SNY 118.56
- EPS
- PLD 3.70
- SNY 8.65
- Revenue
- PLD $8,914,974,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- PLD N/A
- SNY $2.01
- Revenue Next Year
- PLD $6.05
- SNY $6.82
- P/E Ratio
- PLD $31.21
- SNY $5.44
- Revenue Growth
- PLD 10.01
- SNY 15.65
- 52 Week Low
- PLD $85.35
- SNY $44.73
- 52 Week High
- PLD $132.39
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- PLD 62.30
- SNY 42.55
- Support Level
- PLD $110.60
- SNY $46.79
- Resistance Level
- PLD $113.98
- SNY $47.69
- Average True Range (ATR)
- PLD 2.03
- SNY 0.71
- MACD
- PLD 0.21
- SNY -0.27
- Stochastic Oscillator
- PLD 89.98
- SNY 32.62
About PLD Prologis Inc.
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1.3 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $60 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.